Meet the Start-ups

June Park | CEO | siRNAgen Therapeutics

June Park, Ph.D., is the CEO of siRNAgen Therapeutics, a clinical-stage RNAi platform company focused on immunology. June trained as a chemical engineer at MIT and has published several papers and patents on RNAi technologies from her time working at the Langer Lab and siRNAgen Therapeutics. As a Gates Cambridge Scholar, she pursued her Ph.D. in Chemistry at the University of Cambridge, where she worked on lung tissue and neuro-regeneration technologies using supramolecular chemistry. Between her studies as a healthcare consultant at Putnam Associates, June advised key leadership teams at top biopharma on commercial and pipeline strategies covering the entire pharmaceutical product life cycle.

June is a Termeer Fellow class of 2023 and enjoys playing the violin and exercising outside work.

siRNAgen Therapeutics

siRNAgen Therapeutics specialises in the development of extrahepatic RNA interference (RNAi) based therapies for immunology. Its flagship initiative, SRN-001, harnesses the innovative Self Assembled Micelle inhibitory ribonucleic acid (SAMiRNA™) platform technology to precisely target amphiregulin (AREG), a key growth factor involved in the pathological processes of fibroblast proliferation and myofibroblast transformation, which are central to both fibrosis and cancer progression. Currently, siRNAgen is conducting a groundbreaking first-in-human clinical trial to assess the safety, tolerability, and pharmacokinetics of SRN-001, marking a significant step in the therapeutic application of RNAi technology. The company is keenly seeking strategic partnerships to expand its development efforts, presenting a compelling investment opportunity in the advancement of novel RNAi-based treatments for chronic diseases.